Mohamed Salah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6958018/publications.pdf

Version: 2024-02-01

14	164	1040056 9	1125743 13
papers	citations	h-index	g-index

14	14	14	199
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibitors of 17Î²-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges. Molecular and Cellular Endocrinology, 2019, 489, 66-81.	3.2	24
2	First Dual Inhibitors of Steroid Sulfatase (STS) and 17Î²-Hydroxysteroid Dehydrogenase Type 1 (17Î²-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases. Journal of Medicinal Chemistry, 2017, 60, 4086-4092.	6.4	23
3	Development of novel 2,4-bispyridyl thiopheneâ€“based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives. European Journal of Medicinal Chemistry, 2018, 157, 1031-1050.	5.5	18
4	Development of novel amideâ€“derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. European Journal of Medicinal Chemistry, 2018, 158, 270-285.	5.5	16
5	Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17Î²-HSD1 inhibitor with sub-nanomolar IC 50 for a proof-of-principle study. European Journal of Medicinal Chemistry, 2017, 127, 944-957.	5.5	15
6	First Structureâ€“Activity Relationship of 17Î²-Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the Enzyme. Journal of Medicinal Chemistry, 2016, 59, 10719-10737.	6.4	12
7	Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/Î±-synuclein aggregation inhibitors with neuroprotective effects. European Journal of Medicinal Chemistry, 2022, 227, 113911.	5.5	11
8	Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core. MedChemComm, 2018, 9, 1045-1053.	3.4	10
9	Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis. Biochemical Pharmacology, 2020, 172, 113781.	4.4	10
10	Design, Synthesis, and Biological Characterization of Orally Active 17Î²-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis. Journal of Medicinal Chemistry, 2019, 62, 7289-7301.	6.4	7
11	Development of potential preclinical candidates with promising inÂvitro ADME profile for the inhibition of type 1 and type 2 17Î²-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2019, 178, 93-107.	5.5	6
12	Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17Î²-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing. Journal of Medicinal Chemistry, 2019, 62, 1362-1372.	6.4	5
13	Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases. ACS Chemical Neuroscience, 2021, 12, 4302-4318.	3.5	4
14	Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex. Chemical and Pharmaceutical Bulletin, 2016, 64, 34-41.	1.3	3